Dr. Moul Discusses the Long-Term Tolerability and Efficacy of Degarelix
Judd W. Moul, MD, director, Duke Prostate Center, James H. Semans, MD, Professor of Surgery, Duke University Medical Center, discusses the 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix.
Moul says the study originally compared degarelix to leuprolide to treat men with advanced prostate cancer. Initial results showed that monthly degarelix and monthly leuprolide were equivalent over the first year. However degarelix did better at lowering testosterone levels quickly in the first two months than leuprolide, Moul says.
Now it has been discovered that there are long-term benefits to treating patients with degarelix compared to leuprolide. The disease-free survival appears to be better with degarelix versus leuprolide, Moul says.